Creatv Announces Five Clinical Data Presentations at ASCO 2026MorningStar·May 5 at 09:20 AMSONN.CVRMBIO+0.49%
09:35 ETHengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathyprnewswire·Mar 30 at 08:35 AM01276-4.37%600276-2.43%
Braveheart Bio appoints Marc Evanchik as CSO and Brittany de Temple as SVP, advancing towards global Phase 3 trials.Unusual Whales·Feb 5 at 07:03 AMBBH+1.18%SBIO+1.08%
